Patients between 18 and 84 years were eligible for the analysis if they were new users of GLP1 or DPP4
The integration of natural compound research with these advanced diagnostic technologies represents a transformative shift, moving toward personalized and preventive therapeutic approaches rather than reactive symptomatic management
doi: 10.1016/j.tem.2024.07.012 Summary Keywords glucagon-like peptide-1, type 2 diabetes mellitus, l-cell, metabolic surgery, jejunostomy Citation Wang S, Yuan C, Wang H, Ye X, Ruan S, Yi L, Yang W, Wang Z, Wang N, Li J, Feng X, Li Y, Tian Y and Wang Q (2026) Research progress in precision medicine for type 2 diabetes based on the GLP-1
The timing of these foods matters too